HIGHLIGHTS
- What: TG2 inhibition may protect healthy tissue within the organ from undergoing fibrotic modeling, thereby preventing progression of disease, which the prophylactic application of zampilimab employed in this study aimed to demonstrate.
- Who: Linghong Huang and colleagues from the Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, Biotechnologies, Shanghai, China have published the Article: The effect of TG2-inhibitory monoclonal antibody zampilimab on tissue fibrosis in human in vitro and primate in vivo models of chronic kidney disease, in the Journal: PLOS ONE of 28/07/2023
- How: Using CKD . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.